Dr Robert Dreicer from the Cleveland Clinic, Cleveland, USA, talks to ecancertv at the ASCO GU congress 2014 about the phase III TAK-700 trial testing orteronel plus prednisone in patients with mCRPC.

The study showed that orteronel has clinically meaningful activity, with significant improvements in radiographical progression-free survival, but not overall survival.